

# PVRI 2025 Rio Annual Congress

29 January - 1 February 2025

# **Embracing Heterogeneity**

Windsor Convention & Expo Centre, R. Martinho de Mesquita, 129 - Barra da Tijuca Rio de Janeiro - RJ, 20031-204

SESSION 1: Establishing the framework for the classification & diagnosis of PH worldwide

Moderators: k	Katarina Zeder, Lindsay Forbes, Sonja Bartolome
08:00-08:05	PVRI President's welcome Anna Hemnes
08:05-08:20	PH care in Brazil Rogerio Souza
08:20-08:35	Classification & diagnosis of PH: Updates from the 7th WSPH Gabor Kovacs
08:35-08:50	Omics-based & data-driven approaches to early disease diagnosis Catherine Simpson
08:50-08:57	Basic/translational abstract Speaker TBC
08:57-09:12	CIPHER & CIPHER-MRI studies for early diagnosis of PH loana Preston
09:12-09:27	Advanced medical imaging & AI in PH diagnosis & classification Andy Swift
09:27-09:57	Refreshment break
	Refreshment break Fatiana Kudryashova, Gustavo Heresi, Tim Lahm
Moderators: 7	Tatiana Kudryashova, Gustavo Heresi, Tim Lahm  Cardiopulmonary exercise testing in the diagnosis & phenotyping of PH patients
Moderators: 7 09:57-10:12	Cardiopulmonary exercise testing in the diagnosis & phenotyping of PH patients Khodr Tello Classification & diagnosis of pediatric PH: Updates from the 7th WSPH
Moderators: 7 09:57-10:12 10:12-10:27	Cardiopulmonary exercise testing in the diagnosis & phenotyping of PH patients Khodr Tello  Classification & diagnosis of pediatric PH: Updates from the 7th WSPH Dunbar lvy  Basic/translational abstract
Moderators: 7 09:57-10:12 10:12-10:27 10:27-10:35	Cardiopulmonary exercise testing in the diagnosis & phenotyping of PH patients Khodr Tello  Classification & diagnosis of pediatric PH: Updates from the 7th WSPH Dunbar Ivy  Basic/translational abstract Speaker TBC  CTEPH & CTED approach to early diagnosis & treatment

### SESSION 2: Risk stratification & treatment in the new era of PH therapeutics

Thursday 30 January Windsor Oceanico, Asia, 3rd Floor

Moderators: Pilar Escribano S	Subias, Sue	Gue, Sandeep Sahay

Woodoratoro. 1	nul Esonibuno dubius, due due, dunueep dunuy
13:00-13:15	Developments in risk stratification scores in PH Valentina Mercurio (TBC)
13:15-13:30	RV phenotyping in PH risk stratification & treatment Tim Lahm
13:30-13:37	Basic/translational abstract Speaker TBC
13:37-13:52	The impact of novel therapeutics on the treatment algorithm of PH Sandeep Sahay
13:52-14:07	Surgical Interventions, mechanical support, & transplant in end-stage PH Nayeli Zayas
14:07-14:37	Refreshment break
Moderators: C	Forey Ventetuolo, Athiththan Yogeswaran, Horst Olschewski
14:37-14:52	Approach to the treatment of Group 1 PH patients with co-morbidities Anna Hemnes
14:52-15:07	Risk stratification & treatment of pediatric PH Rolf Berger
15:07-15:15	Basic/translational abstract Speaker TBC
15:15-15:30	Medical & surgical management of CTED & CTEPH Hiromi Matsubara
15:30-16:00	Panel discussion: Realities & challenges of applying PH guidelines for diagnosis & treatment in LMIC Facilitators: Vinicio de Jesus Perez, Werner Seeger, Ana Mocumbi, Gerald Maarman, Mauricio Orozco Levi
16:00-18:00	Poster presentations
18:00-19:30	Drinks Reception



11:05-13:00

Career Catalyst Luncheon

## SESSION 3: Vascular heterogeneity in chronic lung disease

Moderators: Grazyna Kwapiszewska, Shelsey Johnson, Susan Majka (TBC)

08:00-08:05 Introduction

Grazyna Kwapiszewska

08:05-08:20 Clinical aspects of PH heterogeneity in chronic lung disease: Same as PAH

or different?

Corey Ventetuolo (TBC)

08:20-08:35 Translational investigations of PH in fibrotic lung disease models

Andrew Bryant

08:35-08:50 Translational investigations of PH in COPD disease models

Natascha Sommer

08:50-08:57 Abstract

Speaker TBC

08:57-09:05 Abstract

Speaker TBC

09:05-09:20 Panel discussion: Comparison of vascular changes in CLD & PAH

09:20-09:50 Refreshment break

Moderators: David Kiely, Mona Lichtblau

09:50-09:55 Introduction

David Kiely

09:55-10:10 Vasculature in CLD: Imaging insights

Nick Rahaghi

10:10-10:25 Pulmonary vascular heterogeneity: Insights from contemporary

pathological approaches

Rubin Tuder

10:25-10:40 Vascular changes in pediatric chronic lung disease

Steven Abman

10:40-10:47 Abstract

Speaker TBC

10:47-10:55 Abstract

Speaker TBC

10:55-11:10 Panel discussion: Should we target vascular changes in chronic lung disease?

11:10-13:00 Lunch break, Barra Restaurant

11:10-13:00 Women in PH Luncheon, sponsored by UTC

Host: Anna Hemnes

Guest speakers: Jill Maron, Karin Tran-Lundmark,

Ana Olga Mocumbi



#### SESSION 4: Heterogeneity in PH associated with heart disease

Friday
31 January
Windsor Oceanico

Moderators: N 13:00-13:05 13:05-13:20 13:20-13:35 13:35-13:42 13:42-13:50	Introduction Nidhy Varghese How do HFrEF & HFpEF affect the pulmonary vasculature & how can we model it? Charly Lai  Congenital heart disease & the pulmonary vasculature Michael Gatzoulis (TBC)  Abstract Speaker TBC	
13:05-13:20 13:20-13:35 13:35-13:42	Nidhy Varghese  How do HFrEF & HFpEF affect the pulmonary vasculature & how can we model it? Charly Lai  Congenital heart disease & the pulmonary vasculature Michael Gatzoulis (TBC)  Abstract Speaker TBC	
13:20-13:35 13:35-13:42	Charly Lai  Congenital heart disease & the pulmonary vasculature  Michael Gatzoulis (TBC)  Abstract  Speaker TBC	
13:35-13:42	Michael Gatzoulis (TBC)  Abstract  Speaker TBC	
	Speaker TBC	•
13:42-13:50		
	Abstract Speaker TBC	
13:50-14:05	Animal models of heart disease PH Wolfgang Kübler	
14:05-14:20	Effect of pre and post-tricuspid shunts on the pulmonary vasculature Rachel Hopper	
14:20-14:50	Refreshment break	
Moderators:	Harm Jan Bogaard, Evan Brittain, Philipp Douschan	
14:50-14:55	Introduction Harm Jan Bogaard	
14:55-15:10	How can we study the right ventricle to develop novel therapies? Edda Spiekerkoetter	
15:10-15:25	Advances in imaging RV function in humans & animal models with PH Rebecca Vanderpool	
15:25-15:32	Abstract Speaker TBC	
15:32-15:40	Abstract Speaker TBC	
15:40-15:55	Cellular heterogeneity in RV dysfunction Soni Savai-Pullamsetti	
15:55-16:10	Managing RV dysfunction in resource-limited settings Prashant Bobhate	
16:10-16:30	Panel discussion	
16:30-18:00	Poster presentations	
19:00-23:59	Gala Dinner & Award Presentations	
	15:25-15:32 15:32-15:40 15:40-15:55 15:55-16:10 16:10-16:30 16:30-18:00	Rebecca Vanderpool  15:25-15:32 Abstract Speaker TBC  15:32-15:40 Abstract Speaker TBC  15:40-15:55 Cellular heterogeneity in RV dysfunction Soni Savai-Pullamsetti  15:55-16:10 Managing RV dysfunction in resource-limited settings Prashant Bobhate  16:10-16:30 Panel discussion  16:30-18:00 Poster presentations



#### SESSION 5: The individual exposome & its contribution to PH heterogeneity

Moderators: La	an 7han	Navnoet	Dhillon Ha	rry Karmout	v Quintana	(TRC)
IVIOUEI ators. La	ari Zilau.	INAVITEEL		iii v Naiiiiout	v Quii ilai ia	11001

08:00-08:15	Drug exposures and PH Vinicio de Jesus Perez
08:15-08:30	Infectious exposures & pulmonary vascular disease Rudolf Oliveira
08:30-08:45	High altitude exposure and PH Silvia Ulrich
08:45-09:00	Early life exposures and pulmonary vascular disease

09:00-09:15 The Microbiome in PH

Sasha Prisco

Kara Goss

09:15-09:45 Refreshment break

#### Moderators: Flavia Navarro, Luke Howard, Nicolas Kolaitis (TBC)

moderators. T	navia Navarre, Eake Newara, Needlae Kelanie (120)
09:45-10:00	Less considered exposures that contribute to PH Stephen Chan
10:00-10:15	Real world activity and exercise perception in PH patients - MyHeart Counts Niamh Errington
10:15-10:30	Insights from All of Us/EHR Evan Brittain
10:30-10:37	Abstract Speaker TBC
10:38-10:45	Abstract Speaker TBC
10:45-11:00	Exposome as a modifiable factor for PH management Bradley Maron

#### 11:00-12:45 Lunch break, Barra Restaurant

11:00-12:00	H	lot to	pics	s fro	om	P۱	R		Go	D	eep)	
-------------	---	--------	------	-------	----	----	---	--	----	---	------	--

Chairs: Martin Wilkins, Paul Hassoun, Werner Seeger

Overview of the GoDeep meta-registry

Werner Seeger

 Risk scores beyond group 1 PH – baseline and follow-up Athiththan Yogeswaran

Survival outcomes and Impact of targeted PAH therapy in PoPH

• PAH-targeted therapies in group 3 PH – PDE5 inhibitor therapy associated with improved survival

Khodr Tello

• Male survival disadvantage in PH: independent of etiology, age, disease severity, comorbidities and treatment, but race-dependent Evan Brittain

#### **SESSION 6: Quantifying therapeutic responses**

Saturday 1 February

Windsor Oceanico, Asia, 3rd Floor

Moderators: Patricia Thistlethwaite, Andy Sweatt, Steeve Provencher  ASIa, 3rd Floor						
12:45-13:00 How should we define disease modification? Roham Zamanian						
13:00-13:15	Developing imaging surrogates of vascular histology to quantify reverse remodeling Karin Tran Lundmark					
13:15-13:23	Abstract - Digital endpoints & monitoring Speaker TBC					
13:23-13:30	Abstract - Molecular classification Speaker TBC					
13:30-13:45	A joint talk with PVRI and PHA USA Patient reported outcomes Frances Varian  Pulmonary Hypertension Association Empowered by hope					

#### SESSION 7: Leveraging disease heterogeneity in clinical trial design

Refreshment break

moderatore. T	zo, carro zoopora, rraviroot emigri
14:15-14:30	What is a platform trial? Charlotte Summers
14:30-14:45	Global perspective & digital trials Caio Tavares
14:45-15:00	Update in pediatric clinical trials Maria Jesus del Cerro

Steve Niederer

#### Dragon's Den / Shark Tank

13:45-14:15

16:00-16:15	Building and testing a personal digital twin for PH
15:50-16:00	Summary Martin Wilkins
15:35-15:50	CRAVE: Canadian Right ventricular AdaptiVE platform trial Jason Weatherald
15:20-15:35	Stratosphere Baysian trial for BMPR2 mutation carriers Sofia Villar
15:05-15:20	PHoenix trial (Rationalising current treatments using implanted devices) Alex Rothman
15:00-15:05	Dragon Den introduction Martin Wilkins
Dragons/Sharks: Sonja Bartolome, Ardeshir Ghofrani, Charlotte Summers	

